<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03114254</url>
  </required_header>
  <id_info>
    <org_study_id>ON/2012/4233</org_study_id>
    <secondary_id>2014-002336-14</secondary_id>
    <secondary_id>CabazL05881</secondary_id>
    <nct_id>NCT03114254</nct_id>
  </id_info>
  <brief_title>A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &amp;/or Metastatic Carcinoma of the Penis</brief_title>
  <acronym>JAVA-P</acronym>
  <official_title>A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &amp;/or Metastatic Carcinoma of the Penis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Bristol NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Bristol NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An evaluation of the activity of cabazitaxel chemotherapy in relapsed cancer of the penis.
      Safety and tolerability will be monitored and survival will be assessed. It is hypothesised
      that cabazitaxel is useful in increasing progression free survival in relapsed penile cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First line treatment of penile cancer often combines Docetaxel, Cisplatin and 5Fluouracil
      (5FU) and there is currently no United Kingdom standard second line agent. Carbazitaxel has
      been shown to kill both taxane resistant and sensitive cells. JAVA-P is a phase two, single
      arm study of the use of carbazitaxel for relapsed, locally advanced or metastatic carcinoma
      of the penis. Seventeen patients will be recruited over two years, with adverse events and
      progression free survival being assessed. Results may indicate the need for larger studies to
      evaluate carbazitaxel as a first line agent.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 5, 2014</start_date>
  <completion_date type="Actual">November 16, 2016</completion_date>
  <primary_completion_date type="Actual">November 16, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response</measure>
    <time_frame>18 weeks</time_frame>
    <description>Complete response recorded from the start of the treatment to completion of 6 cy-cles of treatment determined by radiological response assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Partial response</measure>
    <time_frame>18 weeks</time_frame>
    <description>Partial response recorded from the start of the treatment to completion of 6 cy-cles of treatment determined by radiological response assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Until patient progresses, which is approximately 6 weeks after randomisation</time_frame>
    <description>Progression free survival defined as the time from registration to the first of one of the following: development of radiological disease progression (RECIST 1.1) or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Until patient dies, which is approximately 3 months after randomisation</time_frame>
    <description>Overall survival defined as time from registration to the date of death due to from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity (Defined by number of CTCAE v4.03 Adverse Events, Adverse Reactions and by grades and the worst grade).</measure>
    <time_frame>After each cycle (every 3 weeks) for maximally 6 cycles therefore 18 weeks whilst on treatment and at the 3 month visit timepoint</time_frame>
    <description>Acute toxicity (Defined by number of CTCAE v4.03 Adverse Events, Adverse reactions and by grades experienced by the patient collected at study visits and recorded on an Adverse Event Case report form. .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity (Defined by number of CTCAE v4.03 Adverse Events, Adverse Reactions and by grades and the worst grade).</measure>
    <time_frame>From 3 months post treatment Cycle 1 Day 1 to up to 6 months recorded at the 3 month and 6 month timepoint.</time_frame>
    <description>Late toxicity (Defined by number of CTCAE v4.03 Adverse Events, Adverse reactions and by grades experienced by the patient collected at study visits and recorded on an Adverse Event Case report form. .</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Penile Neoplasm</condition>
  <arm_group>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six cycles of chemotherapy comprising:
Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabazitaxel</intervention_name>
    <description>Six cycles of chemotherapy comprising:
Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days.</description>
    <arm_group_label>Cabazitaxel</arm_group_label>
    <other_name>Jetvana</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically-proven squamous cell carcinoma of the penis

          -  Performance status ECOG 0-2

          -  Written informed consent

          -  Measurable disease as per RECIST 1.1

          -  Fit to receive cabazitaxel as second line chemotherapy

          -  Previously received TPF or cisplatin-5FU as first line systemic chemotherapy for
             penile cancer

          -  Adequate organ function as evidenced by the following peripheral blood counts and
             serum biochemistry at enrollment:

               -  Neutrophils ≥1.5 x 109/L

               -  Haemoglobin ≥10 g/dL

               -  Platelets ≥100 x 109/L

               -  Total bilirubin &lt;1.5 upper limit of normal (ULN)

               -  Alanine aminotransferase/serum glutamate pyruvate transaminase (ALT/SGPT) ≤1.5 x
                  ULN

               -  Serum creatinine ≤1.5 x ULN. (If creatinine is 1.0-1.5 x ULN, creatinine
                  clearance will be calculated according to CKD-EPI formula and patients with a
                  creatinine clearance &lt;60 ml/min should be excluded.)

        Exclusion Criteria:

          -  Pure veruccous carcinoma of the penis

          -  Squamous carcinoma of the urethra

          -  T1 N1 M0 disease

          -  T2 N1 M0 disease

          -  Unfit for this regimen (as assessed by the multidisciplinary team)

          -  Contraindication to chemotherapy

          -  ECOG Performance Status &gt; 2

          -  Active Grade ≥2 peripheral neuropathy

          -  Active secondary cancers

          -  Other concurrent serious illness or medical conditions

          -  Electrocardiogram (ECG) evidence of uncontrolled cardiac arrhythmias, angina pectoris,
             and/or hypertension, history of congestive heart failure, or myocardial infarction
             within last 6 months.

          -  Uncontrolled diabetes mellitus.

          -  History of severe hypersensitivity reaction (≥grade 3) to docetaxel

          -  History of severe hypersensitivity reaction (≥grade 3) to polysorbate 80 containing
             drugs

          -  Active infection requiring systemic antibiotic or anti-fungal medication

          -  Participation in another clinical trial with any investigational drug within 30 days
             prior to study registration.

          -  Concurrent or planned treatment with strong inhibitors of cytochrome P450 3A4/5. A
             1-week washout period is necessary for patients who are already on these treatments.

          -  Concurrent or planned treatment with strong inducers of cytochrome P450 3A4/5. A
             1-week washout period is necessary for patients who are already on these treatments.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amit Bahl</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Bristol NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre, Horfield Road</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitty College Hospitals NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Seixas AL, Ornellas AA, Marota A, Wisnescky A, Campos F, de Moraes JR. Verrucous carcinoma of the penis: retrospective analysis of 32 cases. J Urol. 1994 Nov;152(5 Pt 1):1476-8; discussion 1478-9.</citation>
    <PMID>7933188</PMID>
  </reference>
  <reference>
    <citation>Soria JC, Fizazi K, Piron D, Kramar A, Gerbaulet A, Haie-Meder C, Perrin JL, Court B, Wibault P, Théodore C. Squamous cell carcinoma of the penis: multivariate analysis of prognostic factors and natural history in monocentric study with a conservative policy. Ann Oncol. 1997 Nov;8(11):1089-98.</citation>
    <PMID>9426328</PMID>
  </reference>
  <reference>
    <citation>Cubilla AL, Ayala MT, Barreto JE, Bellasai JG, Nöel JC. Surface adenosquamous carcinoma of the penis. A report of three cases. Am J Surg Pathol. 1996 Feb;20(2):156-60.</citation>
    <PMID>8554104</PMID>
  </reference>
  <reference>
    <citation>Somogyi L, Kálmán E. Metaplastic carcinoma of the penis. J Urol. 1998 Dec;160(6 Pt 1):2152-3.</citation>
    <PMID>9817349</PMID>
  </reference>
  <reference>
    <citation>Tomic S, Warner TF, Messing E, Wilding G. Penile Merkel cell carcinoma. Urology. 1995 Jun;45(6):1062-5.</citation>
    <PMID>7771012</PMID>
  </reference>
  <reference>
    <citation>Kim ED, Kroft S, Dalton DP. Basal cell carcinoma of the penis: case report and review of the literature. J Urol. 1994 Nov;152(5 Pt 1):1557-9. Review.</citation>
    <PMID>7933201</PMID>
  </reference>
  <reference>
    <citation>Bundrick WS, Culkin DJ, Mata JA, Gonzalez E, Zitman R, Venable DD. Penile malignant melanoma in association with squamous cell carcinoma of the penis. J Urol. 1991 Nov;146(5):1364-5. Review.</citation>
    <PMID>1942294</PMID>
  </reference>
  <reference>
    <citation>Oppenheim AR. Sebaceous carcinoma of the penis. Arch Dermatol. 1981 May;117(5):306-7.</citation>
    <PMID>7224661</PMID>
  </reference>
  <reference>
    <citation>Wood EW, Gardner WA Jr, Brown FM. Spindle cell squamous carcinoma of the penis. J Urol. 1972 Jun;107(6):990-1.</citation>
    <PMID>5033986</PMID>
  </reference>
  <reference>
    <citation>Srinivas V, Morse MJ, Herr HW, Sogani PC, Whitmore WF Jr. Penile cancer: relation of extent of nodal metastasis to survival. J Urol. 1987 May;137(5):880-2.</citation>
    <PMID>3573181</PMID>
  </reference>
  <reference>
    <citation>Ravi R. Correlation between the extent of nodal involvement and survival following groin dissection for carcinoma of the penis. Br J Urol. 1993 Nov;72(5 Pt 2):817-9.</citation>
    <PMID>8281416</PMID>
  </reference>
  <reference>
    <citation>Slaton JW, Morgenstern N, Levy DA, Santos MW Jr, Tamboli P, Ro JY, Ayala AG, Pettaway CA. Tumor stage, vascular invasion and the percentage of poorly differentiated cancer: independent prognosticators for inguinal lymph node metastasis in penile squamous cancer. J Urol. 2001 Apr;165(4):1138-42.</citation>
    <PMID>11257655</PMID>
  </reference>
  <reference>
    <citation>Solsona E, Iborra I, Rubio J, Casanova JL, Ricós JV, Calabuig C. Prospective validation of the association of local tumor stage and grade as a predictive factor for occult lymph node micrometastasis in patients with penile carcinoma and clinically negative inguinal lymph nodes. J Urol. 2001 May;165(5):1506-9.</citation>
    <PMID>11342906</PMID>
  </reference>
  <reference>
    <citation>Hussein AM, Benedetto P, Sridhar KS. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer. 1990 Feb 1;65(3):433-8.</citation>
    <PMID>2297633</PMID>
  </reference>
  <reference>
    <citation>Shammas FV, Ous S, Fossa SD. Cisplatin and 5-fluorouracil in advanced cancer of the penis. J Urol. 1992 Mar;147(3):630-2.</citation>
    <PMID>1538445</PMID>
  </reference>
  <reference>
    <citation>Ahmed T, Sklaroff R, Yagoda A. Sequential trials of methotrexate, cisplatin and bleomycin for penile cancer. J Urol. 1984 Sep;132(3):465-8.</citation>
    <PMID>6206239</PMID>
  </reference>
  <reference>
    <citation>Gagliano RG, Blumenstein BA, Crawford ED, Stephens RL, Coltman CA Jr, Costanzi JJ. cis-Diamminedichloroplatinum in the treatment of advanced epidermoid carcinoma of the penis: a Southwest Oncology Group Study. J Urol. 1989 Jan;141(1):66-7.</citation>
    <PMID>2642312</PMID>
  </reference>
  <reference>
    <citation>Sklaroff RB, Yagoda A. Cis-diamminedichloride platinum II (DDP) in the treatment of penile carcinoma. Cancer. 1979 Nov;44(5):1563-5.</citation>
    <PMID>498030</PMID>
  </reference>
  <reference>
    <citation>Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RD; EORTC Genito-Urinary Tract Cancer Group. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008 Jul;19(7):1304-7. doi: 10.1093/annonc/mdn149. Epub 2008 Apr 15.</citation>
    <PMID>18417462</PMID>
  </reference>
  <reference>
    <citation>Oudard S. TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer. Future Oncol. 2011 Apr;7(4):497-506. doi: 10.2217/fon.11.23.</citation>
    <PMID>21463139</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent</keyword>
  <keyword>Locally advanced</keyword>
  <keyword>Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penile Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

